|
Prognostic value of routine biomarkers in older patients with cancer: Pooled analysis of three prospective cohorts. |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Nutricia; SERVIER |
Travel, Accommodations, Expenses - Nutricia; Roche |
|
|
Honoraria - Bristol-Myers Squibb; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Mylan; Pfizer; Roche; Roche; Roche; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Clinigen Group; Pfizer; Pfizer; Puma Biotechnology; Puma Biotechnology; Puma Biotechnology; Samsung |
Research Funding - HalioDx (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Mylan; Pfizer; Pfizer; Pierre Fabre; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Simone Mathoulin-Pélissier |
No Relationships to Disclose |
|
|
No Relationships to Disclose |